Targeted Medical Pharma, Inc. reported preliminary data indicating that its new amino acid-based oral formulation PERCURA(TM) reduced symptoms of pain and numbness related to peripheral neuropathy in an open-label pilot study. The medical food PERCURA(TM) reduced symptoms of numbness in subjects an average of 57%, after the first 30 days of treatment. The pilot also reported an average 56% reduction in pain among subjects related to peripheral neuropathy after 30 days of treatment.

All subjects are expected to complete the 60-day study by the end of 2012.